Research ArticleClinical Studies
Pathological Complete Response and Prognosis in Patients Receiving Neoadjuvant Paclitaxel and Trastuzumab with and without Anthracyclines for Stage II and III, HER2-positive Operable Breast Cancer: A Single-institute Experience
JUN HORIGUCHI, TETSUNARI OYAMA, DAISUKE TAKATA, NANA ROKUTANDA, RIN NAGAOKA, HIROKI ODAWARA, HIDEAKI TOKINIWA, KATSUNORI TOZUKA, MAMI KIKUCHI, AYAKO SATO and IZUMI TAKEYOSHI
Anticancer Research September 2011, 31 (9) 3041-3046;